{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362262944496558592.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1046/j.1365-2893.2003.00450.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2893.2003.00450.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2893.2003.00450.x"}},{"identifier":{"@type":"NAID","@value":"30014687384"}}],"dc:title":[{"@value":"Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Summary.</jats:title><jats:p>Current therapies for chronic hepatitis B (CHB) have a number of limitations, and better treatment options are needed. Peginterferon <jats:italic>α</jats:italic>‐2a (40 kDa) is superior to conventional interferon <jats:italic>α</jats:italic>‐2a in the treatment of chronic hepatitis C. This is the first report on peginterferon <jats:italic>α</jats:italic>‐2a (40 kDa) in the treatment of CHB. In this phase II study, 194 patients with CHB not previously treated with conventional interferon‐<jats:italic>α</jats:italic> were randomized to receive weekly subcutaneous doses of peginterferon <jats:italic>α</jats:italic>‐2a (40 kDa) 90, 180 or 270 <jats:italic>μ</jats:italic>g, or conventional interferon <jats:italic>α</jats:italic>‐2a 4.5 MIU three times weekly. Twenty‐four weeks of therapy were followed by 24 weeks of treatment‐free follow‐up. All subjects were assessed for loss of hepatitis B e antigen (HBeAg), presence of hepatitis B antibody (anti‐HBe), suppression of hepatitis B virus (HBV) DNA, and normalization of serum alanine transaminase (ALT) after follow‐up.</jats:p><jats:p>At the end of follow‐up, HBeAg was cleared in 37, 35 and 29% of patients receiving peginterferon <jats:italic>α</jats:italic>‐2a (40 kDa) 90, 180 and 270 <jats:italic>μ</jats:italic>g, respectively, compared with 25% of patients on conventional interferon <jats:italic>α</jats:italic>‐2a. The combined response (HBeAg loss, HBV DNA suppression, and ALT normalization) of all peginterferon <jats:italic>α</jats:italic>‐2a (40 kDa) doses combined was twice that achieved with conventional interferon <jats:italic>α</jats:italic>‐2a (24%<jats:italic>vs</jats:italic> 12%; <jats:italic>P</jats:italic> = 0.036). All treatment groups were similar with respect to frequency and severity of adverse events. These results indicate that peginterferon <jats:italic>α</jats:italic>‐2a (40 kDa) is superior in efficacy to conventional interferon <jats:italic>α</jats:italic>‐2a in chronic hepatitis B based on clearance of HBeAg, suppression of HBV DNA, and normalization of ALT.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382262944496558597","@type":"Researcher","foaf:name":[{"@value":"W. G. E. Cooksley"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262944496558601","@type":"Researcher","foaf:name":[{"@value":"T. Piratvisuth"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861293601277569","@type":"Researcher","foaf:name":[{"@value":"S.‐D. Lee"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262944496558592","@type":"Researcher","foaf:name":[{"@value":"V. Mahachai"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861293601277568","@type":"Researcher","foaf:name":[{"@value":"Y.‐C. Chao"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262944496558594","@type":"Researcher","foaf:name":[{"@value":"T. Tanwandee"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262944496558595","@type":"Researcher","foaf:name":[{"@value":"A. Chutaputti"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262944496558593","@type":"Researcher","foaf:name":[{"@value":"W. Yu Chang"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262944496558599","@type":"Researcher","foaf:name":[{"@value":"F. E. Zahm"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262944496558596","@type":"Researcher","foaf:name":[{"@value":"N. Pluck"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13520504"},{"@type":"EISSN","@value":"13652893"}],"prism:publicationName":[{"@value":"Journal of Viral Hepatitis"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2003-06-23","prism:volume":"10","prism:number":"4","prism:startingPage":"298","prism:endingPage":"305"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2893.2003.00450.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2893.2003.00450.x"}],"createdAt":"2004-12-27","modifiedAt":"2023-10-13","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050022476722646656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B"},{"@language":"ja-Kana","@value":"ニホンジン マンセイ Bガタ カンエン カンジャ ニオケル エンテカビル カラ ペグインターフェロンα エノ ソウキ キリカエ オ トモナウ チクジ リョウホウ"},{"@language":"ja","@value":"日本人慢性B型肝炎患者における、エンテカビルからペグインターフェロンαへの早期切り替えを伴う逐次療法"},{"@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon‐α in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232280670208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232550879360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693139692416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Factors associated with the effect of interferon‐α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285707387145984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Type I Interferons Impede Short Hairpin RNA-Mediated RNAi via Inhibition of Dicer-Mediated Processing to Small Interfering RNA"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709456608384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714965416192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664411676544","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Renal Impairment in Chronic Hepatitis B: A Review"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664562973056","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205746563840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Recent Advances in Hepatitis B Research"},{"@language":"ja","@value":"わが国におけるB型肝炎研究の最近の動向"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679610428672","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Inhibition of CRISPR/Cas9-Mediated Genome Engineering by a Type I Interferon-Induced Reduction in Guide RNA Expression"},{"@value":"Highlighted Paper selected by Editor-in-Chief : Inhibition of CRISPR/Cas9-Mediated Genome Engineering by a Type Ⅰ Interferon-Induced Reduction in Guide RNA Expression"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681218742528","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes"}]},{"@id":"https://cir.nii.ac.jp/crid/1520009407889252992","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"わが国におけるB型肝炎研究の最近の動向"},{"@language":"ja-Kana","@value":"ワガクニ ニ オケル Bガタ カンエン ケンキュウ ノ サイキン ノ ドウコウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750285604864","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Update of research and management of hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291225550106880","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975317212928","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Appropriate use of interferon for treatment of chronic hepatitis B"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1046/j.1365-2893.2003.00450.x"},{"@type":"CIA","@value":"30014687384"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.1248/bpb.b16-00700_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.1111/hepr.12488_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.1089/jir.2014.0234_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.14789/pjmj.55.443_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.4254/wjh.v7.i23.2427_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.7883/yoken.65.476_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.1016/j.jhep.2009.12.036_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.1111/hepr.13050_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.3390/diseases6020052_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.3748/wjg.v21.i27.8249_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.1016/j.virusres.2012.10.027_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"},{"@type":"CROSSREF","@value":"10.1016/j.omtn.2016.12.007_references_DOI_VrSdCcaGr0SZ8xPIvq46lclGRtY"}]}